REG - Smith & Nephew Plc - Director/PDMR Shareholding
I'm LongbridgeAI, I can summarize articles.Smith & Nephew plc announced that Nate Folkert, President of Orthopaedics and a Person Discharging Managerial Responsibilities (PDMR), received share awards on September 1, 2026. These include a Performance Share Award under the 2026 Plan (117,933 shares) and a Restricted Share Award under the 2024 Plan (67,164 shares). Both were calculated using a market price of £11.0265. The performance award vests in March 2029 based on conditions met between 2026 and 2028, while the restricted award vests over three years subject to employment status.
RNS Number : 1554T Smith & Nephew Plc 02 September 2026
SMITH & NEPHEW PLC
2 September 2026
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
This announcement is made in accordance with the UK Market Abuse Regulation (Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018).
1. PERFORMANCE SHARE AWARD MADE UNDER THE PERFORMANCE SHARE PLAN 2026
On 1 September 2026, the following award of US$0.20 ordinary shares (the "Shares") in Smith & Nephew plc (the "Company") has been granted to Nate Folkert under the Smith & Nephew Performance Share Plan 2026. The award has been calculated using a market price of £11.0265, being the average of the quoted closing prices of a Share for the ten (10) dealing days immediately following the announcement of the Company's First Half results on 4 August 2026.
The award will vest on 15 March 2029 subject to the achievement of performance conditions measured over the period 1 January 2026 to 31 December 2028.
The number of shares subject to the above award are shown at maximum vesting. Should less than maximum vesting be achieved, Nate Folkert will receive a reduced number of shares in accordance with actual performance. Nate Folkert will receive an additional number of shares equivalent to the amount of dividend payable per vested share during the relevant performance period.
Reason for the notification | |
Initial notification /Amendment | Initial notification |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
Name | Smith & Nephew plc |
LEI | 213800ZTMDN8S67S1H61 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
Description of the financial instrument, type of instrument | Smith & Nephew plc ordinary shares of USD 0.20 each |
Identification code | ISIN: GB0009223206 |
Nature of the transaction | Performance Share award granted under the Smith & Nephew Performance Share Plan 2026. |
Date of Transaction | 2026 - 09 - 01 |
Place of Transaction | Grant took place outside a trading venue |
Name (Position) | Nate Folkert (President, Orthopaedics) |
Status | PDMR |
Price (£) | 11.0265 |
Volume | 117,933 |
Aggregated information | N/A Single Transaction |
2. AWARD MADE UNDER THE RESTRICTED SHARE PLAN 2024
On 1 September 2026, the following award of US$0.20 ordinary shares (the "Shares") in Smith & Nephew plc (the "Company") were granted to Nate Folkert under the Smith & Nephew Restricted Share Plan 2024. The award has been calculated using a market price of £11.0265, being the average of the quoted closing prices of a Share for the ten (10) dealing days immediately following the announcement of the Company's First Half results on 4 August 2026.
The award will vest in equal annual tranches over three years following the award date. Each vesting is subject to Nate Folkert remaining in the employment of the Group on the vesting dates, not being under notice and not having achieved an "unsatisfactory performance" rating for his personal performance in the year prior to each vesting date.
Nate Folkert will receive an additional number of shares equivalent to the amount of dividend payable per vested share during the relevant vesting period.
Reason for the notification | |
Initial notification /Amendment | Initial notification |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
Name | Smith & Nephew plc |
LEI | 213800ZTMDN8S67S1H61 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
Description of the financial instrument, type of instrument | Smith & Nephew plc ordinary shares of USD 0.20 each |
Identification code | ISIN: GB0009223206 |
Nature of the transaction | Restricted Share award granted under the Smith & Nephew Restricted Share Plan 2024 |
Date of Transaction | 2026 - 09 - 01 |
Place of Transaction | Grant took place outside a trading venue |
Name (Position) | Nate Folkert (President, Orthopaedics) |
Status | PDMR |
Price (£) | 11.0265 |
Volume | 67,164 |
Aggregated information | N/A Single Transaction |
Helen Barraclough
Company Secretary
Smith & Nephew plc
Tel: +44 (0) 1923 477100
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END DSHFLFVVARIFIIR